{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:20Z","timestamp":1788433700368,"version":"build-2803163510"},"reference-count":9,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"DOI":"10.1182\/blood.2025029937","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:31:48Z","timestamp":1763656308000},"page":"2500-2501","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Big cells, bigger BTK resistance in mantle cell lymphoma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"first","affiliation":[{"name":"University of Miami Sylvester Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2025112011314106900_bib1","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.2024026919","article-title":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"10277","key":"2025112011314106900_bib2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2025112011314106900_bib3","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025112011314106900_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2025112011314106900_bib5","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2025112011314106900_bib6","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2025112011314106900_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2025112011314106900_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-KB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"6682","key":"2025112011314106900_bib9","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2500\/2421257\/blood_bld-2025-029937-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2500\/2421257\/blood_bld-2025-029937-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:31:49Z","timestamp":1763656309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/21\/2500\/548140\/Big-cells-bigger-BTK-resistance-in-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":9,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029937","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,20]]},"published":{"date-parts":[[2025,11,20]]}}}